Targeting Epigenetic Resistance in Advanced Prostate Cancer: BET and DNMT Inhibition
E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss BET and DNMT inhibition in lineage-plastic prostate cancer associated with TP53 or RB1 loss.
Read More
Castration-Resistant (CRPC)
Immunotherapy When Nothing Else Works: Rational or Irrational Approach?
Dr. Susan F. Slovin explores why immunotherapy remains a promising strategy for selected patients with advanced prostate cancer, reviewing CAR T-cell therapy, bispecific T-cell engagers, emerging immune targets, and lessons from an exceptional clinical response.
Read More
Controversies with Testosterone Therapy
Dr. Khera reviews controversies in testosterone therapy, including prostate cancer, cardiovascular risk, and evolving treatment roles.
Read More
Radioligand Therapy Update
Radioligand therapy continues to expand across prostate cancer settings with improving outcomes and new strategies.
Read More
Novel Targeted Treatments for Metastatic Prostate Cancer
This presentation reviews emerging targeted therapies for prostate cancer beyond androgen receptor and PSMA-directed approaches.
Read More- 1
- 2